Markiewicz et al
Heres a look at how those differences are showing up across states: Coverage details can change over time and may differ by plan, so its best to check directly with your state Medicaid office or insurance provider for the most up-to-date information
GLP-1 medications may help appropriate patients experience fewer persistent food thoughts, reduced cravings, earlier fullness, and improved GLP-1 Side Effects GLP-1 Side Effects: When Nausea, Constipation, or Fatigue Should Be Discussed With a Doctor GLP-1 medications have helped many appropriate patients rethink weight loss, appetite control, food noise, blood sugar, Sources Eli Lilly: Retatrutide showed positive Phase 3 topline results and remains investigational ClinicalTrials.gov: Retatrutide Phase 3 study record The Lancet Diabetes & Endocrinology: Effects of retatrutide on body composition in people with type 2 diabetes ScienceDirect: Retatrutide body-composition substudy summary The New England Journal of Medicine: TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial Nature Reviews Endocrinology: Balancing weight and muscle loss in GLP-1 receptor agonist therapy JAMA Internal Medicine: Integrating Diet and Physical Activity When Prescribing GLP-1s American Journal of Clinical Nutrition: Nutritional priorities to support GLP-1 therapy for obesity Acta Diabetologica: Muscle loss and GLP-1RA use
"Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality." JAMA Network Open 7.8 (2024): e2423385
Nature 571 , 403407 (2019)
L-myc has been associated with chemoresistance in small cell lung cancer cell lines (154), whereas N-myc expression in a neuroblastoma cell increased resistance to cisplatin and etoposide in patients (143)
